Next-Step Treatment in Viable Parenchymal Neurocysticercosis When Albendazole Monotherapy Has Not Resolved Cysts
This protocol addresses patients with viable parenchymal neurocysticercosis — specifically 1–2 viable parenchymal cysticerci with no elevated intracranial pressure — in whom the initial antiparasitic course did not achieve the expected radiologic outcome.
Clinical Scenario
The patient has viable parenchymal neurocysticercosis with 1–2 viable parenchymal cysticerci and no elevated intracranial pressure. Antiparasitic therapy is indicated in this setting, and initial treatment with albendazole monotherapy is the recommended first approach.
Indication for This Protocol
Prior treatment: Albendazole monotherapy (with adjunctive corticosteroid therapy and antiepileptic drugs where indicated).
Unmet goal: Radiologic resolution of the parenchymal cystic component on MRI was not achieved by 6 months after the end of that initial course.
Persistence of parenchymal cystic lesions beyond this 6-month threshold is the trigger for the retreatment strategy this protocol defines.
Retreatment Approach (partial overview)
Retreatment involves antiparasitic therapy, with options that may include a different agent or a combination antiparasitic strategy. The specific agent selection, sequencing, and course details are laid out in the full protocol.
Complete regimen criteria, agent selection, and all dosing parameters are available in the structured protocol below.
References
DOI: 10.1093/cid/cix1084
- In the absence of elevated intracranial pressure, we recommend use of antiparasitic drugs in all patients with VPN (strong, moderate).
- For patients with 1–2 viable parenchymal cysticerci, we recommend albendazole monotherapy for 10–14 days compared to either no antiparasitic therapy (strong, high) or combination antiparasitic therapy (weak, low).
- We suggest retreatment with antiparasitic therapy for parenchymal cystic lesions persisting for 6 months after the end of the initial course of therapy (weak, low).
- Options for retreatment include a second course of albendazole, switching to praziquantel, or using the combination of albendazole and praziquantel.
View source ↗